Skip to main content
. 2018 Jun 27;5(1):e000800. doi: 10.1136/openhrt-2018-000800

Figure 2.

Figure 2

Safety outcomes with dabigatran etexilate versus warfarin in Latin American (n=956) and non-Latin American (n=17157) patients. BID, twice daily; GI, gastrointestinal; NC, not calculable.